Calpain-dependent clearance of the autophagy protein p62/SQSTM1 is a contributor to ΔpK oncolytic activity in melanoma

Gene Therapy

Volumn 21, Issue 4, 2014, Pages 371-378

  Colunga, A ^a   Bollino, D ^a   Schech, A ^a   Aurelian, L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

breast cancer; CSC; melanoma; ncolytic virotherapy; spheroid cultures

Indexed keywords

AUTOPHAGY PROTEIN 5; CALPASTATIN; CHLOROQUINE; ONCOLYTIC VIRUS; PD 150606; PROTEIN P62; UNCLASSIFIED DRUG; ACRYLIC ACID DERIVATIVE; CALPAIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SQSTM1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL CULTURE; CANCER STEM CELL; CONTROLLED STUDY; MELANOMA; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; VIRUS REPLICATION; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MULTICELLULAR SPHEROID; PATHOLOGY; TUMOR CELL LINE; VIROLOGY;

ACRYLATES; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; AUTOPHAGY; CALPAIN; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; NEOPLASTIC STEM CELLS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SPHEROIDS, CELLULAR; VIRUS REPLICATION;

EID: 84897570280     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.6     Document Type: Article

References (60)

1. Aghi M, Martuza RL. Oncolytic viral therapies-the clinical experience. Oncogene 2005; 24: 7802-7816.
2. Wakimoto H, Kesari S, Farrell CJ, Curry Jr WT, Zaupa C, Aghi M et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 2009; 69: 3472-3481.
3. Zeyaullah M, Patro M, Ahmad I, Ibraheem K, Sultan P, Nehal M et al. Oncolytic viruses in the treatment of cancer: a review of current strategies. Pathol Oncol Res 2012; 18: 771-781.
4. Fukunaga-Kalabis M, Roesch A, Herlyn M. From cancer stem cells to tumor maintenance in melanoma. J Invest Dermatol 2011; 131: 1600-1604.
5. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010; 18: 510-523.
6. Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012; 10: 717-728.
7. Kanai R, Zaupa C, Sgubin D, Antoszczyk SJ, Martuza RL, Wakimoto H et al. Effect of g34.5 deletions on oncolytic herpes simplex virus activity in brain tumors. J Virol 2012; 86: 4420-4431.
8. Todo T. Active immunotherapy: oncolytic virus therapy using HSV-1. Adv Exp Med Biol 2012; 746: 178-186.
9. Senzer NN, Kaufman HL, Amatruda T, Neumunaitis M, Daniels G, Gonzalez R et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27: 5763-5771.
10. Cheema TA, Wakimoto H, Fecci PE, Ning J, Kuroda T, Jeyaretna DS et al. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci USA 2013; 110: 12006-12011.
11. Mahller YY, Williams IP, Baird WH, Mitton B, Grossheim J, Saeki Y et al. Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One 2009; 4: e4235.
12. Pressey JG, Haas MC, Pressey CS, Kelly VM, Parker JN, Gillespie GY et al. CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV. Pediatr Blood Cancer 2013; 60: 45-52.
13. Hong CS, Fellows W, Niranjan A, Alber S, Watkins S, Cohen JB et al. Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection. Gene Ther 2010; 17: 1200-1205.
14. Zhu G, Su W, Jin G, Xu F, Hao S, Guan F et al. Glioma stem cells targeted by oncolytic virus carrying endostatin-angiostatin fusion gene and the expression of its exogenous gene in vitro. Brain Res 2011; 1390: 59-69.
15. Dmitrieva N, Yu L, Viapiano M, Cripe TP, Chiocca EA, Glorioso JC et al. Chon-droitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy. Clin Cancer Res 2011; 17: 1362-1372.
16. Kanai R, Wakimoto H, Martuza RL, Rabkin SD. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clin Cancer Res 2011; 17: 3686-3696.
17. Zhuang X, Zhang W, Chen Y, Han X, Li J, Zhang Y et al. Doxorubicin-enriched, ALDH(br) mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1. BMC Cancer 2012; 12: 549.
18. Colunga AG, Laing JM, Aurelian L. The HSV-2 mutant DeltaPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins. Gene Ther 2010; 17: 315-327.
19. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006; 5: 1136-1144.
20. Nagano S, Perentes JY, Jain RK, Boucher Y. Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. Cancer Res 2008; 68: 3795-3802.
21. Smith CC, Peng T, Kulka M, Aurelian L. The PK domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for immediate-early gene expression and virus growth. J Virol 1998; 72: 9131-9141.
22. Smith CC, Nelson J, Aurelian L, Gober M, Goswami BB. Ras-GAP binding and phosphorylation by herpes simplex virus type 2 RR1 PK (ICP10) and activation of the Ras/MEK/MAPK mitogenic pathway are required for timely onset of virus growth. J Virol 2000; 74: 10417-10429.
23. Laing JM, Gober MD, Golembewski EK, Thompson SM, Gyure KA, Yarowsky PJ et al. Intranasal administration of the growth-compromised HSV-2 vector DeltaRR prevents kainate-induced seizures and neuronal loss in rats and mice. Mol Ther 2006; 13: 870-881.
24. Golembewski EK, Wales SQ, Aurelian L, Yarowsky PJ. The HSV-2 protein ICP10PK prevents neuronal apoptosis and loss of function in an in vivo model of neurodegeneration associated with glutamate excitotoxicity. Exp Neurol 2007; 203: 381-393.
25. Aurelian L. Herpes simplex virus type 2 vaccines: new ground for optimism? Clin Diagn Lab Immunol 2004; 11: 437-445.
26. Rausch V, Liu L, Apel A, Rettig T, Gladkich J, Labsch S et al. Autophagy mediates survival of pancreatic tumour-initiating cells in a hypoxic microenvironment. J Pathol 2012; 227: 325-335.
27. Dufau I, Frongia C, Sicard F, Dedieu L, Cordelier P, Ausseil F et al. Multicellular tumor spheroid model to evaluate spatio-temporal dynamics effect of chemotherapeutics: application to the gemcitabine/CHK1 inhibitor combination in pancreatic cancer. BMC Cancer 2012; 12: 15.
28. Ludwig K, Tse ES, Wang JY. Colon cancer cells adopt an invasive phenotype without mesenchymal transition in 3-D but not 2-D culture upon combined stimulation with EGF and crypt growth factors. BMC Cancer 2013; 13: 221.
29. Loessner D, Flegg JA, Byrne HM, Clements JA, Hutmacher DW. Growth of confined cancer spheroids: a combined experimental and mathematical modelling approach. Integr Biol (Camb) 2013; 5: 597-605.
30. Grimshaw MJ, Cooper L, Papazisis K, Coleman JA, Bohnenkamp HR, Chiapero-Stanke L et al. Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res 2008; 10: R52.
31. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010; 140: 62-73.
32. Perego M, Tortoreto M, Tragni G, Mariani L, Deho P, Carbone A et al. Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells. J Invest Dermatol 2010; 130: 1877-1886.
33. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
34. Valyi-Nagy K, Dosa S, Kovacs SK, Bacsa S, Voros A, Shukla D et al. Identification of virus resistant tumor cell subpopulations in three-dimensional uveal melanoma cultures. Cancer Gene Ther 2010; 17: 223-234.
35. Perkins D, Pereira EF, Gober M, Yarowsky PJ, Aurelian L. The herpes simplex virus type 2 R1 protein kinase (ICP10 PK) blocks apoptosis in hippocampal neurons, involving activation of the MEK/MAPK survival pathway. J Virol 2002; 76: 1435-1439.
36. Yoon YH, Cho KS, Hwang JJ, Lee SJ, Choi JA, Koh JY. Induction of lysosomal dilation, arrested autophagy, and cell death by chloroquine in cultured ARPE-19 cells. Invest Opthalmol Vis Sci 2010; 51: 6030-6037.
37. Egger ME, Huang JS, Yin W, McMasters KM, McNally LR. Inhibition of autophagy with chloroquine is effective in melanoma. J Surg Res 2013; 184: 274-281.
38. Mehrpour M, Esclatine A, Beau I, Codogno P. Overview of macroautophagy regulation in mammalian cells. Cell Res 2010; 20: 748-762.
39. Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell 2010; 140: 313-326.
40. Pyo JO, Yoo SM, Ahn HH, Nah J, Hong SH, Kam TI et al. Overexpression of Atg5 in mice activates autophagy and extends lifespan. Nat Commun 2013; 4: 2300.
41. Komatsu M, Kageyama S, Ichimura Y. p62/SQSTM1/A170: physiology and pathology. Pharmacol Res 2012; 66: 457-462.
42. Moscat J, Diaz-Meco MT p62: a versatile multitasker takes on cancer. Trends Biochem Sci 2012; 37: 230-236.
43. Parkhitko A, Myachina F, Morrison TA, Hindi KM, Auricchio N, Karbowniczek M et al. Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent. Proc Natl Acad Sci USA 2011; 108: 12455-12460.
44. Inoue D, Suzuki T, Mitsuishi Y, Miki Y, Suzuki S, Sugawara S et al. Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adeno-carcinoma. Cancer Sci 2012; 103: 760-766.
45. Rolland P, Madjd Z, Durrant L, Ellis IO, Layfield R, Spendlove I. The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. Endocr Relat Cancer 2007; 14: 73-80.
46. +. Gene Ther 2008; 15: 1397-1409.
47. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010; 466: 133-137.
48. Jaggupilli A, Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol 2012; 2012: 708036.
49. Ali MA, Stepanko A, Fan X, Holt A, Schulz R. Calpain inhibitors exhibit matrix metalloproteinase-2 inhibitory activity. Biochem Biophys Res Commun 2012; 423: 1-5.
50. Darnell GA, Schroder WA, Antalis TM, Lambley E, Major L, Gardner J et al. Human papillomavirus E7 requires the protease calpain to degrade the retinoblastoma protein. J Biol Chem 2007; 282: 37492-37500.
51. Storr SJ, Carragher NO, Frame MC, Parr T, Martin SG. The calpain system and cancer. Nat Rev Cancer 2011; 11: 364-374.
52. Kim JW, Ho WJ, Wu BM. The role of the 3D environment in hypoxia-induced drug and apoptosis resistance. Anticancer Res 2011; 31: 3237-3245.
53. Gong C, Bauvy C, Tonelli G, Yue W, Deloménie C, Nicolas V et al. Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/progenitor cells. Oncogene 2012; 32: 2261-2272.
54. Clarke PG, Puyal J. Autophagic cell death exists. Autophagy 2012; 8: 867-869.
55. Rosenfeldt MT, Ryan KM. The multiple roles of autophagy in cancer. Carcinogenesis 2011; 32: 955-963.
56. Liu H, He Z, Simon HU. Targeting autophagy as a potential therapeutic approach for melanoma therapy. Semin Cancer Biol 2013; 23: 352-360.
57. Lakhter AJ, Sahu RP, Sun Y, Kaufmann WK, Androphy EJ, Travers JB et al. Chloroquine promotes apoptosis in melanoma cells by inhibiting BH3 domain-mediated PUMA degradation. J Invest Dermatol 2013; 133: 2247-2254.
58. Duran A, Linares JF, Galvez AS, Wikenheiser K, Flores JM, Diaz-Meco MT et al. The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell 2008; 13: 343-354.
59. Jariwalla RJ, Aurelian L, Ts'o PO. Immortalization and neoplastic transformation of normal diploid cells by defined cloned DNA fragments of herpes simplex virus type 2. Proc Natl Acad Sci USA 1983; 19: 5902-5906.
60. + cells in the peripheral blood transport herpes simplex virus DNA fragments to the skin of patients with erythema multiforme (HAEM). J Invest Dermatol 2005; 124: 1215-1224.